Clinical Trial Update: Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients [Phase 3]

View source ↗

Summary

Phase 3 efficacy and safety trial comparing Symbicort Turbuhaler with Oxis Turbuhaler in chronic obstructive pulmonary disease; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Oxis Turbuhaler (formoterol)
• Symbicort Turbuhaler (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-10-25